FDA expands use of Merck’s CAPVAXIVE for high-risk children and teens
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated